Assembly Biosciences EBITDA 2012-2026 | ASMB
Assembly Biosciences ebitda from 2012 to 2026. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Assembly Biosciences Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $-14 |
| 2024 | $-49 |
| 2023 | $-66 |
| 2022 | $-93 |
| 2021 | $-90 |
| 2020 | $-64 |
| 2019 | $-104 |
| 2018 | $-92 |
| 2017 | $-52 |
| 2016 | $-45 |
| 2015 | $-30 |
| 2014 | $-24 |
| 2013 | $-20 |
| 2012 | $-25 |
| 2011 | $-34 |
|
Assembly Biosciences Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-7 |
| 2026-03-31 | $-12 |
| 2025-12-31 | $19 |
| 2025-09-30 | $-11 |
| 2025-06-30 | $-11 |
| 2025-03-31 | $-10 |
| 2024-12-31 | $-12 |
| 2024-09-30 | $-12 |
| 2024-06-30 | $-13 |
| 2024-03-31 | $-12 |
| 2023-12-31 | $-21 |
| 2023-09-30 | $-15 |
| 2023-06-30 | $-18 |
| 2023-03-31 | $-19 |
| 2022-12-31 | $-23 |
| 2022-09-30 | $-23 |
| 2022-06-30 | $-24 |
| 2022-03-31 | $-23 |
| 2021-12-31 | $-21 |
| 2021-09-30 | $-19 |
| 2021-06-30 | $-23 |
| 2021-03-31 | $-27 |
| 2020-12-31 | $-39 |
| 2020-09-30 | $-4 |
| 2020-06-30 | $7 |
| 2020-03-31 | $-28 |
| 2019-12-31 | $-29 |
| 2019-09-30 | $-26 |
| 2019-06-30 | $-20 |
| 2019-03-31 | $-29 |
| 2018-12-31 | $-27 |
| 2018-09-30 | $-22 |
| 2018-06-30 | $-27 |
| 2018-03-31 | $-17 |
| 2017-12-31 | $-13 |
| 2017-09-30 | $-12 |
| 2017-06-30 | $-14 |
| 2017-03-31 | $-14 |
| 2016-12-31 | $-12 |
| 2016-09-30 | $-12 |
| 2016-06-30 | $-10 |
| 2016-03-31 | $-11 |
| 2015-12-31 | $-8 |
| 2015-09-30 | $-7 |
| 2015-06-30 | $-7 |
| 2015-03-31 | $-7 |
| 2014-12-31 | $-6 |
| 2014-09-30 | $-11 |
| 2014-06-30 | $-3 |
| 2014-03-31 | $-4 |
| 2013-12-31 | $-6 |
| 2013-09-30 | $-5 |
| 2013-06-30 | $-5 |
| 2013-03-31 | $-4 |
| 2012-12-31 | $-4 |
| 2012-09-30 | $-5 |
| 2012-06-30 | $-7 |
| 2012-03-31 | $-8 |
| 2011-12-31 | $-19 |
| 2011-09-30 | $-5 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.519B | $0.072B |
| Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |